Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
Adv Rheumatol
; 60: 32, 2020. tab, graf
Article
em En
| LILACS
| ID: biblio-1130792
Biblioteca responsável:
BR1.1
ABSTRACT
Abstract Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.(AU)
Palavras-chave
Texto completo:
1
Índice:
LILACS
Assunto principal:
Cloroquina
/
Doenças Reumáticas
/
Hidroxicloroquina
Limite:
Humans
Idioma:
En
Revista:
Adv Rheumatol
Assunto da revista:
Artrite
/
Reumatologia
Ano de publicação:
2020
Tipo de documento:
Article